These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35191815)

  • 1. India and the COVID-19 vaccine.
    Satish KP
    Hum Vaccin Immunother; 2022 Dec; 18(1):2033541. PubMed ID: 35191815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?
    Joshi G; Borah P; Thakur S; Sharma P; Mayank ; Poduri R
    Hum Vaccin Immunother; 2021 Dec; 17(12):4714-4740. PubMed ID: 34856868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omicron, a new SARS-CoV-2 variant: assessing the impact on severity and vaccines efficacy.
    Joshi G; Poduri R
    Hum Vaccin Immunother; 2022 Dec; 18(1):2034458. PubMed ID: 35240913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccine hesitancy among medical students in India.
    Jain J; Saurabh S; Kumar P; Verma MK; Goel AD; Gupta MK; Bhardwaj P; Raghav PR
    Epidemiol Infect; 2021 May; 149():e132. PubMed ID: 34011421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines and Public Trust: Containing COVID-19 in Cuba.
    Gorry C
    MEDICC Rev; 2022 Jan; 24(1):9-13. PubMed ID: 35157633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative analysis on the safety and efficacy of Covaxin versus other vaccines against COVID-19: a review.
    Talukder A; Kalita C; Neog N; Goswami C; Sarma MK; Hazarika I
    Z Naturforsch C J Biosci; 2022 Jul; 77(7-8):351-362. PubMed ID: 35245422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of immune response and vaccination strategies of SARS-CoV-2 in the phase of viral red queen dynamics.
    Jacob JJ; John Fletcher G; Monisha Priya T; Veeraraghavan B; Mutreja A
    Indian J Med Microbiol; 2021; 39(4):417-422. PubMed ID: 34454775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revisiting regulatory framework in India for accelerated vaccine development in pandemics with an evidence-based fast-tracking strategy.
    Dinda AK; Tripathi SK; John B
    Indian J Med Res; 2020 Jul & Aug; 152(1 & 2):156-163. PubMed ID: 32952146
    [No Abstract]   [Full Text] [Related]  

  • 11. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Building public trust: a response to COVID-19 vaccine hesitancy predicament.
    Vergara RJD; Sarmiento PJD; Lagman JDN
    J Public Health (Oxf); 2021 Jun; 43(2):e291-e292. PubMed ID: 33454769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Will COVID-19 vaccine equity be possible in India?
    Mathivathanan K
    Vaccine; 2021 Aug; 39(35):4928-4929. PubMed ID: 34330556
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.
    Desai D; Khan AR; Soneja M; Mittal A; Naik S; Kodan P; Mandal A; Maher GT; Kumar R; Agarwal A; Gowda NR; H V; Kumar P; Pandey S; Pandey RM; Kumar A; Ray A; Jorwal P; Nischal N; Choudhary A; Brijwal M; Madan K; Lodha R; Sinha S; Dar L; Wig N; Guleria R
    Lancet Infect Dis; 2022 Mar; 22(3):349-356. PubMed ID: 34826383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval.
    Tumban E
    Viruses; 2020 Dec; 13(1):. PubMed ID: 33396343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2.
    Sharma D
    Expert Rev Vaccines; 2021 Sep; 20(9):1051-1057. PubMed ID: 34313516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
    Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
    Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccination in the Indian blood donors: Adjudging the impact on the deferral period.
    Bansal N; Raturi M
    Transfus Clin Biol; 2021 Aug; 28(3):310-312. PubMed ID: 33857620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine certificate during domestic traveling: a potential initiative to prevent COVID-19 waves in India.
    Choudhary OP; Priyanka ; Singh I
    Hum Vaccin Immunother; 2021 Oct; 17(10):3487-3488. PubMed ID: 34170790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. India's COVID-vaccine woes - by the numbers.
    Padma TV
    Nature; 2021 Apr; 592(7855):500-501. PubMed ID: 33854229
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.